Considering rare data provided for NRAS mutations in stage II/III colon cancer, large population cohort investigation for this gene mutation detection should be performed, as NRAS closely related to KRAS and NRAS mutation was prognostic for EGFR MoAbs therapy inmCRC28. The gene discussed is KRAS; the disease is colonic neoplasm.